GSK : FDA Approves Nucala As Add-on Maintenance Treatment For Chronic Obstructive Pulmonary Disease
(RTTNews) - GSK plc. (GSK, GSK.L) announced that the US Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
